Implant Sciences' President Featured on CNN & BBC Regarding Russian Airline Incident

WILMINGTON, Mass., Nov. 10, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, announced that the company's President, Robert Liscouski, (also former Assistant Secretary for Infrastructure Protection at the U.S. Department of Homeland Security) appeared on CNN's Situation Room and BBC's World News America, commenting about aviation security and the Russian Metrojet Incident. He was also interviewed by Government Security News (GSN) and appeared in a featured article in the publication.

The news coverage focused on the recent downing of a Russian passenger jet, and allegations that an explosive device may have been the cause of the crash. Metrojet Flight 9268 crashed Saturday in Egypt's Sinai Peninsula after breaking apart in midair, killing all 224 people on board.

The links to the stories are viewable at our website: http://www.implantsciences.com/inthenews. Alternatively, you can view the video of the interview with CNN at http://cnn.it/1MpxBfQ and the article with the interview with GSN at http://bit.ly/1L77Zio.

"We've got excellent security procedures here in the United States. We look at all aspects of passenger screening, checked baggage, we look at air cargo screening requirements," Robert Liscouski, Implant Sciences' President, stated on BBC World News. "We have substantial security for air cargo going on in the United States, which is domestically originating. It's subject to physical search, x-ray search, the use of explosives trace detection, and dogs for certain cargo. So the big concern comes in with cargo that originates overseas and comes on passenger aircraft to the U.S. They will be reviewing those procedures very carefully."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116

SOURCE Implant Sciences Corporation

Related Links

http://www.implantsciences.com